AVEO Pharmaceuticals Inc. (AVEO)

1.78
0.04 1.90
NASDAQ : Health Technology
Prev Close 1.82
Open 1.84
Day Low/High 1.78 / 1.86
52 Wk Low/High 1.40 / 3.59
Volume 300.64K
Avg Volume 2.27M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 243.17M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer

AVEO And Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib With Sunitinib In First-Line Kidney Cancer

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced plans to initiate a new clinical study, TAURUS ( Tivoz Anib Use ve Rs Us Sutent in advanced renal cell carcinoma (RCC): Patient...

ASCO '12 Stocks: Winners and Losers

ASCO '12 Stocks: Winners and Losers

Snap judgments in biotech and drug stocks after a weekend spent at the ASCO cancer meeting.

ASCO 2012 Live Blog -- Saturday

ASCO 2012 Live Blog -- Saturday

TheStreet's biotech columnist Adam Feuerstein brings you live coverage of ASCO, the Super Bowl of cancer drug medical conferences.

AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO

AVEO Oncology To Host Conference Call And Webcast To Review Phase 3 TIVO-1 Data Presented At ASCO

AVEO Oncology (Nasdaq: AVEO) today announced that the AVEO management team will host a conference call on Monday, June 4, 2012 at 7:30 a.

AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference

AVEO Oncology To Present At The Jefferies 2012 Global Healthcare Conference

AVEO Oncology (Nasdaq: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5, 2012 at 3:00 p.

AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors

AVEO Initiates Phase 1 Study Of AV-203, An ERBB3 Inhibitory Antibody, In Advanced Solid Tumors

AVEO Oncology (Nasdaq: AVEO) today announced the initiation of a Phase 1 study examining the safety and preliminary efficacy of AV-203 along with exploratory biomarkers in patients with advanced solid tumors.

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Thursday with 1.4 million shares changing hands. It is currently at four times its average daily volume and trading down 70 cents (-5.6%).

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)

ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update)

Array Biopharma, Exelixis,Onyx Pharma and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.

AVEO And Astellas Announce Positive Findings From TIVO-1 Superiority Study Of Tivozanib In First-Line Advanced RCC

AVEO And Astellas Announce Positive Findings From TIVO-1 Superiority Study Of Tivozanib In First-Line Advanced RCC

AVEO Oncology (NASDAQ:AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that detailed data from TIVO-1 ( Tivozanib Versus S orafenib in 1 st line Advanced RCC), will be presented on June 2 in an oral...

ASCO '12 Abstract Dump: Cancer Stocks in Focus

ASCO '12 Abstract Dump: Cancer Stocks in Focus

Array Biopharma, Exelixis, Aveo and Pharmacyclics among cancer drug developers releasing new data ahead of the big ASCO meeting.

AVEO Reports First Quarter 2012 Financial Results And Recent Developments

AVEO Reports First Quarter 2012 Financial Results And Recent Developments

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today reported consolidated financial results for the first quarter of 2012 and reviewed key first quarter accomplishments.

AVEO Announces Preliminary Results Of Exploratory Phase 2 Study Evaluating HGF Inhibitor In First-Line Patients With Advanced Lung Cancer

AVEO Announces Preliminary Results Of Exploratory Phase 2 Study Evaluating HGF Inhibitor In First-Line Patients With Advanced Lung Cancer

AVEO Pharmaceuticals Inc. (NASDAQ: AVEO) announced today preliminary data from the exploratory, randomized Phase 2 study comparing the combination of ficlatuzumab and gefitinib, an EGFR tyrosine kinase inhibitor (TKI),...

AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. To Present At Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that the company’s management will present a company overview at upcoming investment conferences.

Biotech Stock Mailbag: AVI, Aveo, Spectrum

Biotech Stock Mailbag: AVI, Aveo, Spectrum

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For First Quarter Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's first quarter ended March 31, 2012 will be released before the market opens on Thursday, May 3, 2012.

AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology

AVEO Announces Publication Of Positive Tivozanib Phase 2 Clinical Trial Results In Journal Of Clinical Oncology

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that previously reported results from a successful Phase 2 clinical trial evaluating the efficacy and safety of tivozanib in 272 patients with advanced renal ...

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Wednesday as it is currently trading at $11.22, below its previous 52-week low of $11.28 with 36,912 shares traded as of 10:10 a.m. ET. Average volume has been 272,200 shares over the past 30 days.

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals Inc. Stock Downgraded (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) has been downgraded by TheStreet Ratings from from a hold to sell.

Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

Data On AVEO Pharmaceuticals’ Tivozanib And AV-203 To Be Presented At AACR Annual Meeting 2012

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that previously reported clinical data on tivozanib, AVEO’s lead product candidate designed to optimally block the VEGF pathway by inhibiting all three...

7 Cancer Drug Stocks to Know Right Now

7 Cancer Drug Stocks to Know Right Now

A first look at the cancer drug stocks that could run up in value as we get closer to the big ASCO conference.

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Monday as it is currently trading at $12.36, below its previous 52-week low of $12.42 with 134,988 shares traded as of 12:39 p.m. ET. Average volume has been 306,900 shares over the past 30 days.

Next Big Thing in Biotech: Cancer Drug Stocks

Next Big Thing in Biotech: Cancer Drug Stocks

Senior columnist Adam Feuerstein explains why cancer drug stocks are the next big thing in biotech.

AVEO Pharmaceuticals To Present At The Cowen And Company 32nd Annual Health Care Conference

AVEO Pharmaceuticals To Present At The Cowen And Company 32nd Annual Health Care Conference

AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, president and chief executive officer, is scheduled to present at the Cowen and Company 32 nd Annual Health Care Conference on Monday, March...

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Stock Hits New 52-Week Low (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) hit a new 52-week low Tuesday as it is currently trading at $12.92, below its previous 52-week low of $13 with 446,169 shares traded as of 2:40 p.m. ET. Average volume has been 306,900 shares over the past 30 days.

AVEO Reports 2011 Financial Results And Highlights Fourth Quarter Progress

AVEO Reports 2011 Financial Results And Highlights Fourth Quarter Progress

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today reported consolidated 2011 financial results and reviewed key progress achieved with its tivozanib and ficlatuzumab development programs in the fourth quarter of 2011.

AVEO Pharmaceuticals, Inc. Announces Timing For Fourth Quarter And Year-End 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. Announces Timing For Fourth Quarter And Year-End 2011 Financial Results, Webcast And Conference Call

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that financial results for the company's fourth quarter and year ended December 31, 2011 will be released before the market opens on Tuesday, February 14, 2012.

AVEO Pharmaceuticals To Present At Several Upcoming Investment Conferences

AVEO Pharmaceuticals To Present At Several Upcoming Investment Conferences

AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) today announced that members of the company’s management team are scheduled to present a corporate overview at several upcoming investment conferences.

J.P. Morgan Biotech Confab Live Chat

J.P. Morgan Biotech Confab Live Chat

TheStreet's Adam Feuerstein will give his impressions of the J.P. Morgan Healthcare Conference and answer readers' biotech investing questions.

AVEO Rises On Unusually High Volume (AVEO)

AVEO Rises On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Wednesday with 901,612 shares changing hands. It is currently at four times its average daily volume and trading up 39 cents (+2.8%).

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Stock Falls On Unusually High Volume (AVEO)

AVEO Pharmaceuticals (Nasdaq:AVEO) is trading at unusually high volume Tuesday with 1.6 million shares changing hands. It is currently at seven times its average daily volume and trading down $2.80 (-16.3%).

TheStreet Quant Rating: D- (Sell)